Trial Outcomes & Findings for Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics (NCT NCT02049359)

NCT ID: NCT02049359

Last Updated: 2023-07-03

Results Overview

Change in A1C from baseline

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

170 participants

Primary outcome timeframe

12 weeks

Results posted on

2023-07-03

Participant Flow

Participant milestones

Participant milestones
Measure
Control Group
Care as usual; no bidirectional texting
Texting
Bidirectional texting weekly for 12 weeks Texting: Bidirectional texting once weekly for 12 weeks
Overall Study
STARTED
95
75
Overall Study
COMPLETED
69
56
Overall Study
NOT COMPLETED
26
19

Reasons for withdrawal

Reasons for withdrawal
Measure
Control Group
Care as usual; no bidirectional texting
Texting
Bidirectional texting weekly for 12 weeks Texting: Bidirectional texting once weekly for 12 weeks
Overall Study
Lost to Follow-up
26
19

Baseline Characteristics

Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control Group
n=69 Participants
Care as usual; no bidirectional texting
Texting
n=56 Participants
Bidirectional texting weekly for 12 weeks Texting: Bidirectional texting once weekly for 12 weeks
Total
n=125 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
65 Participants
n=5 Participants
51 Participants
n=7 Participants
116 Participants
n=5 Participants
Age, Categorical
>=65 years
4 Participants
n=5 Participants
5 Participants
n=7 Participants
9 Participants
n=5 Participants
Age, Continuous
50.4 years
STANDARD_DEVIATION 9.7 • n=5 Participants
52.5 years
STANDARD_DEVIATION 10.3 • n=7 Participants
51.3 years
STANDARD_DEVIATION 10.0 • n=5 Participants
Sex: Female, Male
Female
41 Participants
n=5 Participants
32 Participants
n=7 Participants
73 Participants
n=5 Participants
Sex: Female, Male
Male
28 Participants
n=5 Participants
24 Participants
n=7 Participants
52 Participants
n=5 Participants
Race/Ethnicity, Customized
African American
50 Participants
n=5 Participants
42 Participants
n=7 Participants
92 Participants
n=5 Participants
Race/Ethnicity, Customized
Caucasian
15 Participants
n=5 Participants
10 Participants
n=7 Participants
25 Participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
2 Participants
n=5 Participants
1 Participants
n=7 Participants
3 Participants
n=5 Participants
Race/Ethnicity, Customized
Other
2 Participants
n=5 Participants
3 Participants
n=7 Participants
5 Participants
n=5 Participants
Region of Enrollment
United States
69 Participants
n=5 Participants
56 Participants
n=7 Participants
125 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 12 weeks

Change in A1C from baseline

Outcome measures

Outcome measures
Measure
Control Group
n=69 Participants
Care as usual; no bidirectional texting
Texting
n=56 Participants
Bidirectional texting weekly for 12 weeks Texting: Bidirectional texting once weekly for 12 weeks
Change From Baseline A1C
1.1 percentage of A1C decrease
Interval 0.6 to 1.6
1.4 percentage of A1C decrease
Interval 0.9 to 1.8

SECONDARY outcome

Timeframe: 12 weeks

Population: Change in A1C percentage from baseline by demographic characteristics

Change in A1C from baseline based on age, gender, race, type and duration of diabetes

Outcome measures

Outcome measures
Measure
Control Group
n=69 Participants
Care as usual; no bidirectional texting
Texting
n=56 Participants
Bidirectional texting weekly for 12 weeks Texting: Bidirectional texting once weekly for 12 weeks
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
>65 years
0.8 percentage of A1C decrease
Interval 0.33 to 1.9
1.2 percentage of A1C decrease
Interval 0.2 to 2.2
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
Age 18-35
2.1 percentage of A1C decrease
Interval 0.3 to 4.0
1.9 percentage of A1C decrease
Interval 0.5 to 2.0
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
36-55 years
1.2 percentage of A1C decrease
Interval 0.5 to 1.8
1.4 percentage of A1C decrease
Interval 0.8 to 2.1
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
56-65 years
0.5 percentage of A1C decrease
Interval 0.2 to 1.2
1.5 percentage of A1C decrease
Interval 0.5 to 2.6
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
African American
1.2 percentage of A1C decrease
Interval 0.5 to 1.7
1.3 percentage of A1C decrease
Interval 0.7 to 1.8
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
Caucasian
1.0 percentage of A1C decrease
Interval 0.2 to 1.7
1.4 percentage of A1C decrease
Interval 0.8 to 2.0
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
Hispanic
2.0 percentage of A1C decrease
Sample inadequate to describe 95% confidence intervals
0.9 percentage of A1C decrease
Sample inadequate to describe 95% confidence intervals
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
Other
1.0 percentage of A1C decrease
Sample inadequate to describe 95% confidence intervals
3.0 percentage of A1C decrease
Sample inadequate to describe 95% confidence intervals
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
Female
0.9 percentage of A1C decrease
Interval 0.3 to 1.4
1.3 percentage of A1C decrease
Interval 0.8 to 1.7
Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes
Male
1.4 percentage of A1C decrease
Interval 0.6 to 2.4
1.5 percentage of A1C decrease
Interval 0.7 to 2.4

Adverse Events

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Texting

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Smith

Campbell University

Phone: 2522439800

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place